Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Increased to $45.00 by Analysts at HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) had its price objective upped by HC Wainwright from $35.00 to $45.00 in a research note released on Monday morning, The Fly reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also recently weighed in on DAWN. Bank of America started coverage on shares of Day One Biopharmaceuticals in a research note on Thursday, December 1st. They issued a buy rating and a $34.00 price target for the company. Piper Sandler increased their price objective on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an overweight rating in a research report on Sunday. Needham & Company LLC started coverage on shares of Day One Biopharmaceuticals in a research report on Wednesday, December 14th. They set a buy rating and a $40.00 price objective for the company. Finally, The Goldman Sachs Group started coverage on shares of Day One Biopharmaceuticals in a research report on Monday, December 5th. They set a buy rating and a $45.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of Buy and a consensus target price of $43.50.

Day One Biopharmaceuticals Price Performance

Day One Biopharmaceuticals stock opened at $21.89 on Monday. The firm has a 50 day simple moving average of $20.75 and a 200-day simple moving average of $20.79. Day One Biopharmaceuticals has a 1-year low of $5.44 and a 1-year high of $28.35.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last posted its quarterly earnings results on Monday, November 7th. The company reported ($0.53) earnings per share for the quarter, meeting the consensus estimate of ($0.53). Equities analysts forecast that Day One Biopharmaceuticals will post -2.18 EPS for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, Director Julie Papanek Grant sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $20.04, for a total value of $100,200.00. Following the completion of the transaction, the director now owns 424,358 shares of the company’s stock, valued at approximately $8,504,134.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Day One Biopharmaceuticals news, Director Julie Papanek Grant sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $20.04, for a total value of $100,200.00. Following the completion of the transaction, the director now owns 424,358 shares of the company’s stock, valued at approximately $8,504,134.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeremy Bender sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 1st. The shares were sold at an average price of $20.03, for a total transaction of $250,375.00. Following the completion of the transaction, the chief executive officer now directly owns 1,215,375 shares of the company’s stock, valued at approximately $24,343,961.25. The disclosure for this sale can be found here. Insiders sold 119,178 shares of company stock valued at $2,458,187 in the last 90 days. Company insiders own 8.70% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp raised its holdings in shares of Day One Biopharmaceuticals by 60.9% in the 3rd quarter. Bank of New York Mellon Corp now owns 102,223 shares of the company’s stock valued at $2,048,000 after purchasing an additional 38,681 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Day One Biopharmaceuticals by 9.5% in the 3rd quarter. California State Teachers Retirement System now owns 10,929 shares of the company’s stock valued at $219,000 after purchasing an additional 944 shares in the last quarter. State Street Corp raised its holdings in shares of Day One Biopharmaceuticals by 469.1% in the 3rd quarter. State Street Corp now owns 2,041,738 shares of the company’s stock valued at $40,896,000 after purchasing an additional 1,682,955 shares in the last quarter. Tang Capital Management LLC acquired a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $8,012,000. Finally, Price T Rowe Associates Inc. MD raised its stake in Day One Biopharmaceuticals by 2.6% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 2,094,913 shares of the company’s stock worth $41,962,000 after acquiring an additional 53,569 shares in the last quarter. 86.08% of the stock is currently owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

See Also

The Fly logo

Analyst Recommendations for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.